Modified vaccinia ankara

DB15483ApprovedInvestigationalVaccines

Modified vaccinia ankara is a live, non-replicating orthopoxvirus vaccine used to prevent smallpox, monkeypox, and other diseases caused by vaccinia virus. Vaccines using MVA are live and non-replicating, and are produced using Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN).

Mechanism: Vaccination with Modified Vaccinia Ankara elicits humoral and cellular immune responses to orthopoxviruses, thereby providing host protection against future orthopoxvirus infections.
Curator reviewed · 1 reference
Primary indication: Modified vaccinia ankara is a vaccine indicated for the prevention of smallpox and monkeypox disease in adults 18 years of age and older determined to be at high risk for smallpox or monkeypox infection.Curator reviewed · 6 structured indications
First approval: Canada, 2013 · United States, 2021 · European Union, 2020
Also known as: Modified Vaccinia Virus (Ankara-Bavarian Nordic) · Vaccinia strain modified ankara
Brand names: Imvanex
Jynneos

Resolves to

Compound

UNIITU8J357395

Clinical / RWD

RxNorm1668221

What you can answer from here — as of April 02, 2025

303Drug interactionsStructured to mechanism, not free text

102Clinical trialsPhase, status and sponsor resolved per trial

6Structured indicationsCondition, population, route and combination as fields, not prose

1ContraindicationEach with its own population and attribute set

10Marketed productsAcross 4 countries and 2 labellers

4+ReferencesStructured and connected to the statements they support

Which other approved drugs treat the same conditions as Modified vaccinia ankara, and which companies have late-stage candidates in those indications?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account